Bioactivity | O-2050 is a high affinity cannabinoid CB1 receptor antagonist with a Ki of 2.5 nM. O-2050 inhibits cannabinoid CB2 receptor (Ki=0.2 nM). O-2050 can cause locomotor stimulation in mice[1]. |
In Vivo | O-2050 (1, 3, 10, 30 mg/kg; ip; pretreatment 30 mins) produces significant and dose-dependent decreases in food intake in mice. O-2050 (10, 30 mg/kg) significantly causes locomotor stimulation[1]. |
Name | O-2050 |
CAS | 1883545-42-3 |
Formula | C23H31NO4S |
Molar Mass | 417.56 |
Transport | Room temperature in continental US; may vary elsewhere. |
Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
Reference | [1]. Jenny L Wiley, et al. Structural and pharmacological analysis of O-2050, a putative neutral cannabinoid CB(1) receptor antagonist. Eur J Pharmacol. 2011 Jan 25;651(1-3):96-105. |